Skip to main content
. 2013 Feb 1;48(2):143–152. doi: 10.1310/hpj4802-143

Table 3.

Adverse reactions reported in ≥2% of linaclotide-treated (290 mcg) patients and at an incidence greater than in placebo group patients in the 2 phase 3, placebo-controlled trials (1 and 2) in irritable bowel syndrome with constipation1

Adverse reactions Linaclotide 290 mcg (n = 807) Placebo (n = 798)
Diarrhea 20% 3%

Abdominal pain 7% 5%

Flatulence 4% 2%

Headache 4% 3%

Viral gastroenteritis 3% 1%

Abdominal distension 2% 1%